Literature DB >> 23466308

The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort.

Greta Pells1, George F Mells, Marco Carbone, Julia L Newton, Andrew J Bathgate, Andrew K Burroughs, Michael A Heneghan, James M Neuberger, Darren B Day, Samantha J Ducker, Richard N Sandford, Graeme J Alexander, David E J Jones.   

Abstract

BACKGROUND & AIMS: Liver transplantation improves survival in end-stage primary biliary cirrhosis (PBC), but the benefit for systemic symptoms including fatigue is less clear. The aim of this study was to utilise the comprehensive UK-PBC Research Cohort, including 380 post-transplant patients and 2300 non-transplanted patients, to answer key questions regarding transplantation for PBC.
METHODS: Cross-sectional study of post-transplant PBC patients and case-matched non-transplanted patients. Detailed clinical information was collected, together with patient systemic symptom impact data using validated assessment tools.
RESULTS: Over 25% of patients in the transplant cohort were grafted within 2 years of PBC diagnosis suggesting advanced disease at presentation. Transplanted patients were significantly younger at presentation than non-transplanted (mean 7 years) and >35% of all patients in the UK-PBC cohort who presented under 50 years had already undergone liver transplantation at the study censor point (>50% were treatment failures (post-transplant or unresponsive to UDCA)). Systemic symptom severity (fatigue and cognitive symptoms) was identical in female post-transplant patients and matched non-transplanted controls and unrelated to disease recurrence or immunosuppression type. In males, symptoms were worse in transplanted than in non-transplanted patients.
CONCLUSIONS: Age at presentation is a major risk factor for progression to transplant (as well as UDCA non-response) in PBC. Although both confirmatory longitudinal studies, and studies utilising objective as well as subjective measures of function, are needed if we are to address the question definitively, we found no evidence of improved systemic symptoms after liver transplantation in PBC and patients should be advised accordingly. Consideration needs to be given to enhancing rehabilitation approaches to improve function and life quality after liver transplant for PBC.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2013        PMID: 23466308      PMCID: PMC6976302          DOI: 10.1016/j.jhep.2013.02.019

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  36 in total

1.  Fatigue and physical function after orthotopic liver transplantation.

Authors:  Mette Aadahl; Bent Adel Hansen; Preben Kirkegaard; Mogens Groenvold
Journal:  Liver Transpl       Date:  2002-03       Impact factor: 5.799

2.  Benefit of transplantation in primary biliary cirrhosis between 1985-1997.

Authors:  Jill Tinmouth; George Tomlinson; E Jenny Heathcote; Leslie Lilly
Journal:  Transplantation       Date:  2002-01-27       Impact factor: 4.939

3.  Physical activity long-term after liver transplantation yields better quality of life.

Authors:  Witold Rongies; Sylwia Stepniewska; Monika Lewandowska; Edyta Smolis-Bak; Wlodzimierz Dolecki; Janusz Sierdzinski; Ewa Trzepla; Grazyna Cholewinska; Wanda Stankiewicz
Journal:  Ann Transplant       Date:  2011 Jul-Sep       Impact factor: 1.530

4.  Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence.

Authors:  Julia L Newton; G John Gibson; Mark Tomlinson; Katharine Wilton; David Jones
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

5.  Central nervous system dysfunction in primary biliary cirrhosis and its relationship to symptoms.

Authors:  Claire McDonald; Julia Newton; H Ming Lai; Stuart N Baker; David E Jones
Journal:  J Hepatol       Date:  2010-08-11       Impact factor: 25.083

6.  Differences in health-related quality of life scores after orthotopic liver transplantation with respect to selected socioeconomic factors.

Authors:  Sammy Saab; Hillary Bownik; Noel Ayoub; Zobair Younossi; Francisco Durazo; Steven Han; Johnny C Hong; Douglas Farmer; Ronald W Busuttil
Journal:  Liver Transpl       Date:  2011-05       Impact factor: 5.799

7.  Cost of a quality-adjusted life year in liver transplantation: the influence of the indication and the model for end-stage liver disease score.

Authors:  Fredrik Åberg; Suvi Mäklin; Pirjo Räsänen; Risto P Roine; Harri Sintonen; Anna-Maria Koivusalo; Krister Höckerstedt; Helena Isoniemi
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

8.  Cognitive impairment in primary biliary cirrhosis: symptom impact and potential etiology.

Authors:  Julia L Newton; Kieren G Hollingsworth; Roy Taylor; Ahmed M El-Sharkawy; Zia Uda Khan; Ruth Pearce; Kathryn Sutcliffe; Oke Okonkwo; Adrian Davidson; Jennifer Burt; Andrew M Blamire; David Jones
Journal:  Hepatology       Date:  2008-08       Impact factor: 17.425

9.  Cyclosporin A treatment increases rat soleus muscle oxidative capacities.

Authors:  Hervé Sanchez; Benoit N'Guessan; Florence Ribera; Renée Ventura-Clapier; Xavier Bigard
Journal:  Muscle Nerve       Date:  2003-09       Impact factor: 3.217

10.  Quality of life before and after liver transplantation for cholestatic liver disease.

Authors:  C R Gross; M Malinchoc; W R Kim; R W Evans; R H Wiesner; J L Petz; J S Crippin; G B Klintmalm; M F Levy; P Ricci; T M Therneau; E R Dickson
Journal:  Hepatology       Date:  1999-02       Impact factor: 17.425

View more
  15 in total

Review 1.  Novel therapeutic targets in primary biliary cirrhosis.

Authors:  Jessica K Dyson; Gideon M Hirschfield; David H Adams; Ulrich Beuers; Derek A Mann; Keith D Lindor; David E J Jones
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-02-03       Impact factor: 46.802

2.  PBC: Better Solutions to Beat Feeling Beat.

Authors:  Naw April Phaw; David E J Jones
Journal:  Dig Dis Sci       Date:  2019-08       Impact factor: 3.199

Review 3.  [Modern treatment of primary biliary cholangitis].

Authors:  C P Strassburg
Journal:  Internist (Berl)       Date:  2018-01       Impact factor: 0.743

4.  Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.

Authors:  Jennifer Y Lee; Christopher J Danford; Hirsh D Trivedi; Elliot B Tapper; Vilas R Patwardhan; Alan Bonder
Journal:  Dig Dis Sci       Date:  2019-01-10       Impact factor: 3.199

Review 5.  Posttransplant considerations in autoimmune liver disease: Recurrence of disease and de novo.

Authors:  Alexis Gumm; Antonio Perez-Atayde; Andrew Wehrman
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-10-10

6.  The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study.

Authors:  David E J Jones; Aaron Wetten; Ben Barron-Millar; Laura Ogle; George Mells; Steven Flack; Richard Sandford; John Kirby; Jeremy Palmer; Sophie Brotherston; Laura Jopson; John Brain; Graham R Smith; Steve Rushton; Rebecca Jones; Simon Rushbrook; Douglas Thorburn; Stephen D Ryder; Gideon Hirschfield; Jessica K Dyson
Journal:  EBioMedicine       Date:  2022-05-21       Impact factor: 11.205

7.  Diagnosis and management of patients with primary biliary cirrhosis.

Authors:  Jessica Dyson; David Jones
Journal:  Clin Liver Dis (Hoboken)       Date:  2014-04-01

Review 8.  Liver Transplantation for Patients with Cholestatic Liver Diseases.

Authors:  Wenzel Schöning; Maximilian Schmeding; Florian Ulmer; Anne Andert; Ulf Neumann
Journal:  Viszeralmedizin       Date:  2015-06-08

9.  Fatigue in primary sclerosing cholangitis is associated with sympathetic over-activity and increased cardiac output.

Authors:  Jessica K Dyson; Ahmed M Elsharkawy; Christopher A Lamb; Ahmad Al-Rifai; Julia L Newton; David E Jones; Mark Hudson
Journal:  Liver Int       Date:  2014-12-04       Impact factor: 5.828

10.  Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.

Authors:  Marco Carbone; Alessandra Nardi; Steve Flack; Guido Carpino; Nikoletta Varvaropoulou; Caius Gavrila; Ann Spicer; Jonathan Badrock; Francesca Bernuzzi; Vincenzo Cardinale; Holly F Ainsworth; Michael A Heneghan; Douglas Thorburn; Andrew Bathgate; Rebecca Jones; James M Neuberger; Pier Maria Battezzati; Massimo Zuin; Simon Taylor-Robinson; Maria F Donato; John Kirby; Robert Mitchell-Thain; Annarosa Floreani; Fotios Sampaziotis; Luigi Muratori; Domenico Alvaro; Marco Marzioni; Luca Miele; Fabio Marra; Edoardo Giannini; Eugenio Gaudio; Vincenzo Ronca; Giulia Bonato; Laura Cristoferi; Federica Malinverno; Alessio Gerussi; Deborah D Stocken; Heather J Cordell; Gideon M Hirschfield; Graeme J Alexander; Richard N Sandford; David E Jones; Pietro Invernizzi; George F Mells
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.